Notice of Closed Meeting, 80107 [2020-27229]
Download as PDF
<![CDATA[
80107
Federal Register / Vol. 85, No. 239 / Friday, December 11, 2020 / Notices
microbiologic cure, (3) Using existing
laboratory specimens, monitor genetic
mutations associated with macrolide or
fluroquinolone antibiotic resistance.
Data captured on the standardized
Case Report Form will be analyzed to
determine outcomes from usage of
second-line antibiotic therapy for
M.gentialium. These data may inform
future CDC STD Treatment Guidelines.
There are an estimated 100 respondents
(anticipated to report once per year)
who will be clinicians in private and
public health care settings. The data
collection is necessary as there are no
current national recommendations for
patients who fail current CDCrecommended therapy for M.
genitalium. Each case report form is
anticipated to take up to 60 minutes to
complete. This data collection provides
CDC with information to determine
which second-line treatments are most
clinically effective, as well as
determining antibiotic resistance
patterns of M. genitalium throughout the
US. There are no costs to respondents
other than their time. The estimated
annualized burden hours for this data
collection are 100 hours.
ESTIMATED ANNUALIZED BURDEN HOURS
Type of respondent
Physician or Nurse Practitioner.
M. genitalium Treatment Failure Registry Case Report Form
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2020–27326 Filed 12–10–20; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
jbell on DSKJLSW7X2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease, Disability,
and Injury Prevention and Control Special
Emphasis Panel (SEP)-DP21–002,
Epidemiologic Cohort Study of Interstitial
Cystitis.
Date: March 30, 2021.
Time: 10:00 a.m.–6:00 p.m., EST.
Place: Teleconference.
Agenda: To review and evaluate grant
applications.
VerDate Sep<11>2014
23:25 Dec 10, 2020
No. of Respondents
Form name
Jkt 253001
For Further Information Contact: Jaya
Raman Ph.D., Scientific Review Officer, CDC,
4770 Buford Highway, Mailstop F80, Atlanta,
Georgia 30341, Telephone: (770) 488–6511,
JRaman@cdc.gov.
The Director, Strategic Business Initiatives
Unit, Office of the Chief Operating Officer,
Centers for Disease Control and Prevention,
has been delegated the authority to sign
Federal Register notices pertaining to
announcements of meetings and other
committee management activities, for both
the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives
Unit,Office of the Chief Operating
Officer,Centers for Disease Control and
Prevention.
[FR Doc. 2020–27229 Filed 12–10–20; 8:45 am]
100
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Centers for Disease Control and
Prevention (CDC)/Health Resources
and Services Administration (HRSA)
Advisory Committee on HIV, Viral
Hepatitis and STD Prevention and
Treatment (CHACHSPT); Notice of
Charter Renewal
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of charter renewal.
AGENCY:
FOR FURTHER INFORMATION CONTACT:
Jonathan Mermin, MD, MPH,
Designated Federal Officer, Centers for
Disease Control and Prevention (CDC)/
Health Resources and Services
Administration (HRSA) Advisory
Committee on HIV, Viral Hepatitis and
STD Prevention and Treatment
(CHACHSPT), CDC, HHS, 1600 Clifton
Road NE, Mailstop US8–6, Atlanta,
Georgia 30329–4027; Telephone (404)
639–8000, JMermin@cdc.gov.
The
Director, Strategic Business Initiatives
Unit, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention, has been delegated the
authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2020–27227 Filed 12–10–20; 8:45 am]
BILLING CODE 4163–18–P
This gives notice under the
Federal Advisory Committee Act of
October 6, 1972, that the Centers for
Disease Control and Prevention (CDC)/
Health Resources and Services
Administration (HRSA) Advisory
Committee on HIV, Viral Hepatitis and
Fmt 4703
1
STD Prevention and Treatment
(CHACHSPT), Centers for Disease
Control and Prevention, Department of
Health and Human Services, has been
renewed for a 2-year period through
November 25, 2022.
SUMMARY:
Frm 00118
Average burden per response
(in hours)
SUPPLEMENTARY INFORMATION:
BILLING CODE 4163–18–P
PO 00000
No. responses
per respondent
Sfmt 9990
E:\FR\FM\11DEN1.SGM
11DEN1
1
]]>Agencies
[Federal Register Volume 85, Number 239 (Friday, December 11, 2020)]
[Notices]
[Page 80107]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-27229]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended, and the Determination of the Director, Strategic
Business Initiatives Unit, Office of the Chief Operating Officer, CDC,
pursuant to Public Law 92-463. The grant applications and the
discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the grant applications, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: Disease, Disability, and Injury Prevention
and Control Special Emphasis Panel (SEP)-DP21-002, Epidemiologic
Cohort Study of Interstitial Cystitis.
Date: March 30, 2021.
Time: 10:00 a.m.-6:00 p.m., EST.
Place: Teleconference.
Agenda: To review and evaluate grant applications.
For Further Information Contact: Jaya Raman Ph.D., Scientific
Review Officer, CDC, 4770 Buford Highway, Mailstop F80, Atlanta,
Georgia 30341, Telephone: (770) 488-6511, [email protected].
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee
management activities, for both the Centers for Disease Control and
Prevention and the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,Office of the Chief
Operating Officer,Centers for Disease Control and Prevention.
[FR Doc. 2020-27229 Filed 12-10-20; 8:45 am]
BILLING CODE 4163-18-P
